Physician profile
Guy T Easterling
NPI 1588660948
$761.07
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $227 · 2021: $211 · 2022: $145.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $128.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $83.92 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $66.02 | 2021-2022 | |
| Abbvie INC. | $65.10 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.58 | 2019-2021 | |
| Pfizer INC. | $64.44 | 2019-2021 | |
| Abbott Laboratories | $34.04 | 2022 | |
| Ironwood Pharmaceuticals, INC | $32.63 | 2020 | |
| Eisai INC. | $30.79 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.23 | 2022 | |
| Allergan, INC. | $22.91 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $21.27 | 2022 | |
| Genentech USA, INC. | $20.43 | 2020 | |
| Biogen, INC. | $20.39 | 2021 | |
| Evoke Pharma, INC. | $18.70 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.76 | 2022 | |
| Lilly USA, LLC | $15.22 | 2020 | |
| Medtronic USA, INC. | $12.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Easterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.